Member Info for Adastra

From the RNS, interest is not restricted to a single player and the division is both specialised and lucrative, hence the advisors.
"Tp has received expressions of interest for the Group's Maritime Engineering business (TPG Maritime Limited) based in Portsmouth, which includes manufacturing facilities and technologies to support mission-critical equipment for submarines and other applications. In light of such interest, the board has appointed advisers to review these opportunities and consider the strategic options for the Group's engineering business"

This should be a substantial figure and would expect multiple interested parties with good funds. A big war chest would accelerate TP's activities in each of the cutting-edge technologies. Excellent, as CEO would not let marine go unless are good premium.

Effectively a bid for TP group, expect lots of interest due to govt and blue-chip income stream.

CEO would only consider substantial bid here so expecting big numbers. Expect tier 1 UK players BAe Bab**** to be interested plus Thales, Nel etc so bidding war could well escalate. Phil Cartmel is well aware of intrinsic value here.

Time for TP to jump into the opportunity!!
The oxygen supply at a hospital under intense strain with coronavirus patients has 'reached a critical situation', according to an internal document.

Bosses at Southend Hospital said there is 'high demand for oxygen' because of rising numbers of Covid-19 patients and they 'are working to manage this'.

Buyers are picking up stock rapidly again. Are they starting to realise (at last) that this little gem is woefully undervalued?? This is worth well in excess of twice the current £48m MCap.... Do the research now and get in at this well under the radar level.

It took the TP group Portsmouth marine team less than 8 weeks to do this. Under trial conditions, the System produced 5 normal cubic metres of oxygen from just 10 litres of water each hour over a ten-hour test period. This would equate to approximately 6 litres of liquid oxygen per hour. The System was able to produce gas within a minute of startup and with an intelligent built-in control system was able to run automatically throughout the test. Surely we can roll this out quickly using existing skills and even RN personnel.

Golden opportunities seldom arise but TP has a superb window at the moment to announce progress on the on-site medical oxygen generator progress. All news channels sre highloghting critical levels of oxygen in hozlitals. Come on TP lets have a progress update on the development announced in the June 2020 RNS. I have emailed the BoD to that effect. Any progress is opportune.
Copied thanks to advfn poster Luzley

The activities of Sapienza, the ESA and then the recent purchase of Osprey is indicative of a definite and focused strategy active at present in one area of TP expertise. There is a lot of activity happening below the surface here building the prospects for big increases in turnover and profit. Its about building a staircase for the future. I agree that expenditure on some projects is not achieving big money at present but just having a foot in the door as a player is massive. TP and its subsidiaries has high respect and provenance.

This is exactly the type of rise that TP has been waiting for. Rather than race and retreat, we are seeing the staircase effect of people and Instos actually researching TP and deciding to take a position. You'll always have the short-term 10% crew but the major change occurring here is the nature of this climb. The graphs show it perfectly. The price steps up as new researchers buy in and a few of the 10% crew drop out. The price retreats BUT back to a higher low than before. Rinse and repeat. This stepwise progression is indicative of really positive upward movement and is beginning to reflect the prospects underneath. Great share; should have a stonking 2021.

I think phase 2 and deployment may well coincide due to urgent NHS requirements so it could well be the next RNS or accompany the t/u expected mid-month.

Listening to the ICU consultant on R4 today the increased need for oxygen within hospitals seems inevitable over the next few months. TP was engaged with partners to advance its proven unit in June (check tbe RNS in June). As I previously stated, this could well be one of the background innovations that has real significance. TP certainly has all the credentials given it's expertise in this field in confined naval submarines.

These dips in price as we progress seem to be excellent opportunities to either increase holdings or take an initial position in a high growth arena. The progress may be bumpy at times but the direction is clear and institutions are going to have to increase their exposure in all the fields in which TP is active. It's just a matter of time and patience. Every active channel of involvement with tier 1 and 2 suppliers is an avenue to growth and exposure. TP will either run ahead on its own or be eaten by a bigger player at a premium to the current dismally low MCap.

Point taken SC although I think Osprey will prove to have been a very astute addition to the capabilities of both Polaris and Sapienza. Phil Cartmel has always had a focussed perspective on the type of group he wanted to build. The addition of the Manchester heavy engineering business and subsequent upgrades had visible merits at the time but carnage in the oil and gas sector and delays in nuclear were clearly draining resources better spent elsewhere. It was ballsy to cut out this £3m pa loss maker as recovery prospects were slow. TP is now clearly defined and specialist in all the areas which you mention. The market is now clearly horizon scanning for TP organic growth in its technology and applications.
In that respect I want to see evidence of the real underlying progress indicated on the Twitter feed.
There is a huge amount of IP tech here and the expertise to unlock it. We appear to have achieved a pivot point of shedding a big loss-making division and exploiting green and advanced capabilities. I don't expect much from the Covid restrained year just ended but I expect much from 2021.

It's not the cost or the need for more and bigger wind farms etc ....the key point has always been storage or use of excess electricity at off peak times. Effective use of the electricity from existing wind farms when demand is low is the key and TP are actively engaged with T1 and T2 players to utilise it to produce and store both H2 and O2. Yes, we need more green energy but TP is rapidly using it's existing tech to produce liquid O2 and 10bar H2 with a view to using that grid excess so the costing is very low.

To dismiss Hygrogen (and more relevant at present) oxygen production totally is a little short-sighted. In June TP announced that In just six weeks they had risen to an initial challenge from the COVID-19 outbreak to successfully test a field-deployable system capable of supplying medical-grade oxygen on demand. They have taken existing equipment available within the technology centre and, with minimal external expense, configure it in new ways to prove that such systems . They stated that they were actively engaged with others to produce a field
deploy able system but did not expect it to have any benefit to y/e Dec 2020. (All in June 2020 RNS). I'm expecting progress on all fronts in the January update and especially this.

Happy to listen to all opinions as that's the basis of good informed investment decisions. Can't disagree with any of previous posters comments save to say that a lot of TP group innovation is starting to see traction now on many fronts. Their provenance in the provision of hydrogen and pure oxygen in the confined submarine environment is directly relevant to current green issues, as is their carbon capture technology. If you research their recent joint projects with international teams you will see what I mean. Similarly, their entry into robotics, space, drone technology, airspace and artificial intelligence is alongside either tier 1 or specialist enterprises. As I have said before, the real difference for me was the decision to divest heavy engineering. It was responsible for a mere £6.5m turnover but whacking up £3m losses... better gone! TP retains the precision engineering that is a vital ingredient of applied tech in its chosen fields. All in all it now looks fit for purpose, streamlined and capable of pushing ahead strongly. I do expect 2020 results to be lacklustre but this year's should be sparkling and I'm looking ahead not back.

Again, good to have investors doing their research and getting on board at this level. The quality of assets here is excellent and the intellectual property significant as TP teams up with so many cutting-edge teams and projects. Any one of which would transform already excellent prospects overnight.

Boom year for TP group 2021. Everything has come together for the company. It now has critical mass in three distinct areas with huge growth prospects. Having got rid of the heavy engineering division that was loss-making and holding it back, this company can now fly....And it will. Too good to miss.

Glad to have you on board. TP Group have so much innovation going on in highly relevant fields at present that I omitted to mention the deployable SOTA oxygen generation equipment which could be highly relevant now.
'Our Portsmouth business has decades of experience in building highly reliable electrolyser-based solutions for demanding applications. In just six weeks they have risen to an initial challenge from the COVID-19 outbreak to successfully test a field-deployable system capable of supplying medical-grade oxygen on demand. '
For the full RNS from June see
https://www.investegate.co.uk/tp-group-plc--tpg-/rns/first-production-of-oxygen-from-new-modular-system/202006080700061829P/
As Phil Cartmel puts it - the potential of this development is a very exciting addition to the future prospects of TP Group."
Bearing in mind that this was undergoing fast-track development mid 2020 and should have progressed substantially from then as he stated at the time: TP Group is already engaged with third parties to specify field-deployable systems for the next phase of development.